Dipeptidyl peptidase-4 inhibitor anagliptin reduces fasting apolipoprotein B-48 levels in patients with type 2 diabetes: A randomized controlled trial
Autor: | Yusuke Seino, Eri Wada, Masahiko Ando, Mariko Furukawa, Norio Okada, Ryoichi Banno, Daisuke Hagiwara, Hiroshi Takagi, Shintaro Iwama, Taku Tsunekawa, Takayuki Okuji, Yoshiaki Morishita, Hiroshi Arima, Tomoko Kobayashi, Hidetaka Suga, Mariko Sugiyama, Motomitsu Goto, Yoji Hamada, Takeshi Onoue, Yoshihiro Ito, Etsuko Yamamori |
---|---|
Rok vydání: | 2019 |
Předmět: |
Male
Apolipoprotein B Blood Pressure Dipeptidyl peptidase-4 inhibitor Type 2 diabetes 030204 cardiovascular system & hematology Biochemistry Vascular Medicine chemistry.chemical_compound 0302 clinical medicine Endocrinology Medicine and Health Sciences Hypolipidemic Agents Multidisciplinary biology Fasting Middle Aged Lipids Lipid Profiles Type 2 Diabetes Cholesterol Anagliptin Medicine lipids (amino acids peptides and proteins) Female Adiponectin Anatomy medicine.drug Research Article medicine.medical_specialty Endocrine Disorders Science Lipoproteins 030209 endocrinology & metabolism 03 medical and health sciences Diabetes mellitus Internal medicine medicine Diabetes Mellitus Humans Triglycerides Aged Dyslipidemias Glycated Hemoglobin Dipeptidyl-Peptidase IV Inhibitors business.industry Cholesterol HDL Biology and Life Sciences Proteins Lipid metabolism Cholesterol LDL medicine.disease Lipid Metabolism Gastrointestinal Tract Pyrimidines Metabolism Apolipoproteins chemistry Diabetes Mellitus Type 2 Metabolic Disorders biology.protein Glycated hemoglobin business Apolipoprotein B-48 Digestive System |
Zdroj: | PLoS ONE PLoS ONE, Vol 15, Iss 1, p e0228004 (2020) |
ISSN: | 1932-6203 |
Popis: | Type 2 diabetes and dyslipidemia are diseases that collectively increase the risk of patients developing cardiovascular complications. Several incretin-based drugs are reported to improve lipid metabolism, and one of these medications, anagliptin, is a dipeptidyl peptidase-4 (DPP-4) inhibitor that has been shown to decrease serum triglyceride and low-density lipoproteins cholesterol. This study aimed to conduct an investigation into the effects of anagliptin on serum lipid profiles. This multicenter, open-label, randomized (1:1), parallel group study was designed to evaluate the effects of anagliptin on serum lipid profiles (triglycerides, lipoproteins, apolipoproteins, and cholesterol fractions). The study involved 24 patients with type 2 diabetes at two participating hospitals for a period of 24 weeks. Patients were randomly assigned to the anagliptin (n = 12) or control (n = 12) groups. Patients in the anagliptin group were treated with 200 mg of the drug twice daily. Patients in the control group did not receive anagliptin, but continued with their previous treatment schedules. Lipid metabolism was examined under fasting conditions at baseline and 24 weeks. Patients treated with anagliptin for 24 weeks exhibited significantly reduced levels of serum apolipoprotein B-48, a marker for lipid transport from the intestine, compared with the control group patients (P < 0.05). After 24 weeks of treatment, serum adiponectin levels were significantly raised, whereas glycated hemoglobin (HbA1c) levels were significantly lower compared with the baseline in the anagliptin group (P < 0.05), but not in the control group. This study showed that the DPP-4 inhibitor anagliptin reduces fasting apolipoprotein B-48 levels, suggesting that this drug may have beneficial effects on lipid metabolism possibly mediated by the inhibition of intestinal lipid transport. |
Databáze: | OpenAIRE |
Externí odkaz: |